Immutep raises $100m and signs with Merck on ‘blockbuster’ drug - (ASX:IMM)

Market Cap (2-Jul) $363,897,504 (530th)	Close (30-Jun) $0.315 0.01 (3.28%)	Volume (30-Jun) 2,012,212	Shortsold (19-Jun) 27,150,697 (1.86%) (138th)
52w High $0.415	52w Low $0.223	P/E 7.50	EPS -0.03

[ARTICLE] Immutep raises $100m and signs with Merck on ‘blockbuster’ drug

MediaBot

June 3, 2024 23:15

A news article has been posted about Immutep on the AFR. The article was published around June 3, 2024 23:15, on 3 June 2024 at 11:15pm.

Gift 5 articles to anyone you choose each month when you subscribe. Immutep says it is less than three years away from a potential “blockbuster drug” after raising $100 million to finalise late-stage trials of its lung cancer treatment. Shares in the ...

Read Article

IMM was $0.32 at the close of trade on 30 June 2023

Recent Articles about ASX:IMM
20-Dec	Immutep MS therapy IMP761 found safe in initial Phase 1 trial data multiplesclerosisnewstoday.com
18-Dec	Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 uk.finance.yahoo.com
17-Dec	Immutep Announces Initial Safety Data From First-In-Human Phase I Trial Evaluating IMP761 menafn.com
17-Dec	Immutep, Monash Reveal LAG-3 Binding to MHC Class II miragenews.com
17-Dec	Health Check: Clinical trials don’t sleigh down for the silly season msn.com
17-Dec	Immutep dips as safety test for flagship drug IMP761 shows no adverse effects msn.com
17-Dec	Immutep Reveals Promising Data for IMP761 Trial markets.businessinsider.com
17-Dec	Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II markets.businessinsider.com
16-Dec	Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II manilatimes.net
16-Dec	Study Sheds Light on New Ways for Immunotherapy to Better Target Cancer technologynetworks.com
Tracked

Find all articles about Immutep, including others on the AFR, on the media page.

You must login or register to post a comment.

You must be logged in to post a reply.

End of Day Prices

Date	Close	Volume	Change
30-Jun	$0.24	2,317,965	0.00 (0.00%)
27-Jun	$0.24	3,596,443	-0.01 (2.04%)
26-Jun	$0.25	9,618,322	+0.02 (6.52%)
24-Jun	$0.23	1,654,877	+0.01 (2.22%)
23-Jun	$0.23	2,623,915	-0.01 (4.26%)
20-Jun	$0.24	1,559,723	0.00 (0.00%)
19-Jun	$0.24	1,515,472	-0.01 (2.08%)
18-Jun	$0.24	3,258,168	-0.01 (2.04%)
16-Jun	$0.25	1,410,792	-0.01 (3.92%)
13-Jun	$0.26	2,467,998	0.00 (0.00%)
12-Jun	$0.26	6,583,523	-0.02 (5.56%)
06-Jun	$0.27	1,031,469	0.00 (0.00%)
05-Jun	$0.27	1,321,412	-0.01 (1.82%)
04-Jun	$0.28	1,790,793	0.00 (0.00%)
03-Jun	$0.28	383,083	-0.01 (1.79%)
2 up, 8 down, and 5 flat days

High $0.32	Low $0.30	Trades 243	Turnover $627,825	Volume 2,012,212
30 June 2023 at 4:10pm

High $0.32	Low $0.30	Trades 243	Turnover $627,825	Volume 2,012,212
30 June 2023 at 4:10pm

Immutep Health Care
Cancer Pharmaceuticals

$0.315 0.010 (3.28%)

IMMUTEP LIMITED Pharmaceuticals, Biotechnology & Life Sciences

[ARTICLE] Immutep raises $100m and signs with Merck on ‘blockbuster’ drug

MediaBot

$0.315 0.010 (3.28%)

Followers

Prices

Announcements

End of Day Prices

IMM Immutep Health Care Cancer Pharmaceuticals

$0.315 0.010 (3.28%)

IMM IMMUTEP LIMITED Pharmaceuticals, Biotechnology & Life Sciences

[ARTICLE] Immutep raises $100m and signs with Merck on ‘blockbuster’ drug

MediaBot

$0.315 0.010 (3.28%)

Followers

Prices

Announcements

End of Day Prices

Immutep Health Care
Cancer Pharmaceuticals

IMMUTEP LIMITED Pharmaceuticals, Biotechnology & Life Sciences